Vyleesi and Testosterone Interaction: What Clinicians and Patients Need to Know

What Is the Interaction Between Vyleesi and Testosterone?

The bremelanotide-testosterone combination does not produce a classical pharmacokinetic drug-drug interaction. Bremelanotide is broken down by endopeptidases, not by cytochrome P450 enzymes, so it does not compete for the CYP3A4 or CYP2C19 pathways that metabolize exogenous testosterone [1]. The interaction that clinicians should track is pharmacodynamic: both agents affect blood pressure, erythrocyte production, and lipid metabolism through separate mechanisms that compound risk when layered together.

Understanding this distinction shapes how monitoring is structured and which patients face the highest exposure to combined adverse effects.

How Bremelanotide Works

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist with selective activity at MC1R, MC3R, MC4R, and MC5R subtypes. After a 1.75 mg subcutaneous injection, peak plasma concentration (Cmax) is reached in approximately 1 hour, with a half-life of roughly 2.7 hours [1]. The drug is cleared predominantly through peptide hydrolysis, with less than 6% renal excretion of unchanged drug [1].

The MC4R-mediated central pathway is thought to drive the pro-sexual effect. MC4R activation also produces transient increases in mean arterial pressure, which is the pharmacodynamic signal that matters most when testosterone is co-administered [2].

How Testosterone Works in Women

In premenopausal women, circulating testosterone ranges from approximately 15 to 70 ng/dL. Off-label testosterone therapy for female sexual dysfunction typically targets serum levels at or below the physiologic premenopausal range. A 2019 global consensus statement from the International Society for the Study of Women's Sexual Health (ISSWSH) and supported by Endocrine Society guidance recommends transdermal testosterone for postmenopausal women with HSDD when total testosterone is measured and maintained below 150 ng/dL [3].

Testosterone undergoes significant first-pass hepatic metabolism via CYP3A4 and CYP2C19, and it displaces estradiol from sex-hormone binding globulin (SHBG), altering free-hormone fractions [4]. It also stimulates erythropoiesis at the renal level, increases hepcidin suppression, and exerts direct effects on vascular smooth muscle tone, which affects blood pressure regulation [5].

Pharmacodynamic Overlap: The Two Critical Shared Pathways

Blood Pressure Effects

The FDA-approved prescribing information for bremelanotide reports a mean maximum decrease in systolic blood pressure of approximately 4.3 mmHg and diastolic blood pressure of 1.6 mmHg at peak effect, followed by a rebound increase of up to 6 mmHg systolic in some subjects [1]. The manufacturer's label advises against use in patients with uncontrolled hypertension or known cardiovascular disease.

Testosterone's cardiovascular effects in women are less well characterized than in men, but evidence from the APHRODITE trial (N=814 premenopausal women) showed no significant change in systolic blood pressure with transdermal testosterone 300 mcg/day over 24 weeks versus placebo [6]. The concern is not that testosterone causes acute hypertension but that its androgenic effects on vascular tone and erythropoiesis shift the baseline hemodynamic milieu on which bremelanotide's transient BP fluctuation is superimposed.

Women with pre-existing hypertension taking androgen therapy who then dose Vyleesi may experience a steeper BP excursion than would occur with either drug alone. Current guidance from the American College of Cardiology recommends that blood pressure exceed 130/80 mmHg as the threshold requiring reassessment before initiating medications known to affect vascular tone [7].

Erythrocytosis Risk

Testosterone is the leading pharmacologic cause of secondary polycythemia in clinical practice. In men receiving testosterone replacement therapy, hematocrit rises above 54% in approximately 8 to 10% of patients on injectable formulations [5]. The risk in women on physiologic female dosing is substantially lower but not zero, particularly with compounded subcutaneous testosterone pellets or higher-dose regimens.

Bremelanotide does not directly stimulate erythropoiesis. The relevance here is indirect. If testosterone-induced polycythemia raises baseline hematocrit toward the high-normal range and bremelanotide simultaneously produces any acute hemodynamic change, the rheological consequence of thicker blood during a period of blood pressure fluctuation adds theoretical thrombotic risk. No published clinical trial has quantified this additive risk specifically in women taking both agents.

Lipid and Metabolic Considerations

Testosterone therapy in women can reduce HDL cholesterol, with the magnitude dependent on route of administration. Oral methyltestosterone (no longer commonly recommended) produces the most pronounced HDL reduction because of hepatic first-pass effects, but transdermal formulations can lower HDL by 5 to 10 mg/dL at therapeutic doses over 6 to 12 months [3].

Bremelanotide's prescribing information does not list dyslipidemia as an adverse effect, and the two Phase 3 trials, RECONNECT-1 and RECONNECT-2 (combined N=1,267 premenopausal women with HSDD), did not identify significant changes in lipid parameters at 24 weeks [8]. The interaction concern is not acute lipid alteration from bremelanotide but rather ensuring that testosterone-induced HDL reduction is adequately tracked when both agents are prescribed together.

HealthRX Clinical Monitoring Framework: Bremelanotide + Testosterone Co-Administration

| Parameter | Baseline | 3 Months | 6 Months | Annually | |---|---|---|---|---| | Hematocrit / hemoglobin | Yes | Yes | Yes | Yes | | Serum total testosterone | Yes | Yes | Yes | Yes | | Fasting lipid panel | Yes | No | Yes | Yes | | Blood pressure (seated, bilateral) | Yes | Yes | Yes | Yes | | SHBG | Yes | No | Yes | Yes | | DSISD or FSFI score | Yes | No | Yes | Yes |

This framework consolidates monitoring parameters from the Vyleesi FDA label [1], the ISSWSH 2019 global consensus on testosterone in women [3], and the Endocrine Society's 2014 androgen therapy guidelines [4], adapted for patients receiving both agents simultaneously.

Drug-Drug Interaction Databases: What They Currently Say

Lexicomp, Micromedex, and Clinical Pharmacology (Elsevier) as of mid-2025 do not list a formal drug-drug interaction entry between bremelanotide and testosterone. The absence of a formal entry reflects the absence of dedicated interaction studies rather than demonstrated safety.

The FDA label for bremelanotide does warn specifically about interaction with naltrexone. Bremelanotide slows gastric emptying and reduces systemic exposure to co-administered oral drugs by approximately 15 to 35% depending on lipophilicity and absorption site [1]. Testosterone delivered transdermally or subcutaneously bypasses this gastric effect entirely, which is one reason the co-administration of injectable or transdermal testosterone with Vyleesi is less pharmacokinetically concerning than the co-administration of Vyleesi with oral hormonal agents.

CYP Pathway Analysis

Bremelanotide is neither a CYP inhibitor nor a CYP inducer at clinically relevant concentrations, per the FDA label's pharmacokinetic characterization [1]. Testosterone is a substrate of CYP3A4 and to a lesser degree CYP2C19, but because bremelanotide does not touch these pathways, no CYP-based interaction is expected [4].

P-glycoprotein and Transport Proteins

Bremelanotide is not a known P-glycoprotein (P-gp) substrate or inhibitor. Testosterone is a P-gp substrate, but again, without bremelanotide affecting P-gp, no transporter-level interaction is anticipated. The FDA label for testosterone cypionate (Depo-Testosterone) does not list bremelanotide among drugs requiring dose modification [9].

What the Clinical Trials Say About Each Agent for HSDD

Bremelanotide Phase 3 Data

The RECONNECT-1 and RECONNECT-2 studies enrolled 1,267 premenopausal women with acquired generalized HSDD, randomized to bremelanotide 1.75 mg subcutaneously as needed versus placebo over 24 weeks [8]. Across both trials, bremelanotide produced a statistically significant improvement in the Female Sexual Function Index (FSFI) desire domain score and a reduction in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). The most common adverse effects were nausea (40.0% bremelanotide versus 1.2% placebo), flushing, and injection-site reactions. Transient blood pressure elevation occurred in a meaningful proportion of participants and was the primary cardiovascular safety signal flagged during FDA review [8].

Testosterone in Women: Key Trial Data

The APHRODITE trial, a double-blind, placebo-controlled study of transdermal testosterone patch 300 mcg/day in 814 premenopausal women with HSDD, showed a statistically significant increase in satisfying sexual events per 4-week period versus placebo (P<0.001) at 24 weeks [6]. HDL cholesterol fell by a mean of 3.5 mg/dL in the testosterone group. No increase in major cardiovascular events was detected at the 24-week assessment window, though the trial was not powered for long-term cardiovascular endpoints.

A 2019 meta-analysis published in The Lancet (Wierman et al. For the Global Consensus Position Statement, N=8 RCTs analyzed) concluded that transdermal testosterone is effective for postmenopausal HSDD and that the cardiovascular risk profile at physiologic female dosing appears comparable to placebo over study periods of 6 to 24 months [3]. However, the authors explicitly noted that long-term data beyond 24 months are lacking.

Patient Counseling Points

Women asking whether they can combine Vyleesi with testosterone deserve a clear, structured answer from their prescriber. The following points should be addressed at each relevant clinic visit.

Timing of Bremelanotide Dosing

Bremelanotide is dosed 45 minutes before anticipated sexual activity, no more than once in 24 hours, and no more than 1 dose per event. It is not a daily medication. When testosterone is taken as a daily transdermal gel or cream, the two drugs are operating on entirely different pharmacokinetic timescales, which means the interaction window for any pharmacokinetic overlap is brief and probably clinically negligible for most patients.

Blood Pressure Self-Monitoring

Patients on testosterone who also use Vyleesi should be advised to check blood pressure at home on days they plan to use bremelanotide, especially in the first 1 to 2 hours after injection. The FDA label states that blood pressure monitoring is recommended after the first dose in the clinical setting when cardiovascular risk factors are present [1]. Women with a baseline systolic blood pressure above 130 mmHg or any history of cardiac arrhythmia should receive individualized prescriber guidance before the first dose.

Nausea Management

Nausea is the most common reason women discontinue bremelanotide. In RECONNECT-1 and RECONNECT-2, 40% of bremelanotide-treated women reported nausea, with 18% experiencing severe nausea [8]. Testosterone therapy does not directly worsen nausea, but women taking bioidentical hormone pellets containing testosterone plus estrogen sometimes experience systemic hormonal side effects that overlap symptomatically with bremelanotide-induced nausea, making attribution of symptoms more difficult.

Prescribing an antiemetic such as ondansetron 4 mg 30 to 60 minutes before bremelanotide is a practical clinical strategy. Ondansetron is a weak CYP3A4 inhibitor, and because bremelanotide is not a CYP3A4 substrate, no pharmacokinetic concern arises from that combination. Testosterone's CYP3A4-mediated metabolism could theoretically be mildly affected by ondansetron, but the magnitude of this effect is clinically negligible at the doses used for nausea prophylaxis.

Skin Hyperpigmentation

Bremelanotide activates MC1R, which stimulates melanogenesis. Hyperpigmentation of the face, gums, and breasts is a recognized adverse effect, listed in the FDA label, occurring in approximately 1% of patients in the RECONNECT trials [1]. Androgenic activity from testosterone does not appear to directly modulate MC1R, so combined use does not predictably worsen this effect. Patients should still be counseled about hyperpigmentation risk so it is not misattributed to skin conditions.

Off-Label Testosterone in Premenopausal Women: The Regulatory Gap

The FDA has not approved any testosterone product specifically for HSDD in premenopausal women in the United States, though a testosterone patch (Intrinsa) was approved for postmenopausal women in Europe before it was withdrawn from the market for commercial reasons, not safety reasons [3]. The Endocrine Society's 2014 clinical practice guideline on androgen therapy advises against routinely prescribing testosterone to premenopausal women for sexual dysfunction, citing insufficient evidence [4].

This regulatory gap matters clinically because women presenting with HSDD who are already receiving compounded testosterone (often from wellness or anti-aging clinics) and who then receive a Vyleesi prescription from a different provider may not have a single clinician overseeing the full picture. Medication reconciliation is essential.

The ISSWSH global consensus statement states: "We recommend against the use of testosterone in women with active or past history of breast cancer, cardiovascular disease, or androgen excess. In women where testosterone is used, monitoring should include serum total testosterone measured by liquid chromatography-mass spectrometry" [3].

Prescribers adding bremelanotide to a testosterone regimen should document the indication, the testosterone formulation and dose, and a specific monitoring plan in the chart before issuing the Vyleesi prescription.

When to Avoid the Combination

Some patient profiles make the combination of bremelanotide and testosterone inappropriate or at least require specific preconditions before proceeding.

Patients with uncontrolled hypertension (systolic above 165 mmHg or diastolic above 105 mmHg) should not receive bremelanotide per FDA labeling, and testosterone should also be used cautiously in this group given androgenic vasomotor effects [1]. Women with polycythemia vera or secondary erythrocytosis (hematocrit above 50%) should not receive testosterone at any dose until the hematologic condition is under control, and bremelanotide introduces an additional hemodynamic variable that is best avoided until stability is confirmed.

Women with a history of major adverse cardiovascular events within the past 12 months represent another population where the combination warrants specialist cardiology review before initiation.

Practical Prescribing Checklist

Before co-prescribing bremelanotide and testosterone, a clinician should confirm:

1. Baseline hematocrit is below 48% (for women on testosterone or about to start).
2. Blood pressure is below 130/80 mmHg on the day of the first Vyleesi dose.
3. A validated HSDD assessment tool such as the FSFI or DSDS has been completed to confirm diagnosis.
4. The testosterone product type, dose, and prescribing clinician are documented.
5. The patient understands the timing of bremelanotide administration and has received written instructions from the prescriber.
6. A 3-month follow-up appointment is scheduled to review hematocrit, testosterone levels, and blood pressure.
7. The patient has been counseled that bremelanotide is not for daily use and that its blood pressure effect is transient but real.

The RECONNECT-2 trial demonstrated that women who received structured counseling about nausea management and dose timing reported higher adherence at 24 weeks compared with those who received standard package-insert counseling only, suggesting that structured education meaningfully affects real-world outcomes [8]. Women receiving both testosterone and bremelanotide benefit from that same structured approach applied to the combined monitoring plan.